Are there documented clinical case reports of ivermectin interacting with common oncology drugs or supportive care medications?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
There are no widely reported clinical case reports documenting harmful or clinically significant drug–drug interactions between ivermectin and standard oncology drugs in the peer‑reviewed literature; most evidence comes from preclinical studies showing interactions at cellular or transporter levels and from regulatory warnings about possible interactions with drugs like blood thinners [1] [2] [3]. Multiple 2024–2025 reviews and case‑series‑level commentary stress the absence of robust human clinical evidence and call for clinical trials and vigilance about potential interactions, especially via P‑glycoprotein and CYP‑related pathways [1] [4] [5].
1. What the literature actually contains: preclinical signals, scarce clinical data
Laboratory and animal studies report biologically plausible interactions: ivermectin modulates signaling pathways (PAK1, EGFR/ERK/Akt/NF‑κB) and can affect drug‑resistance mechanisms and efflux pumps such as P‑glycoprotein (ABCB1), suggesting it could alter concentrations or activity of chemotherapeutics in cells [2] [6] [5]. However, systematic reviews and 2025 oncology overviews emphasize that human clinical evidence is extremely limited — there is no substantial body of case reports or randomized trials showing clinically meaningful interactions in cancer patients to date [1] [4].
2. Clinical trials are beginning but don’t document interaction signals yet
Early phase clinical activity is emerging: a 2025 phase I/II abstract tested ivermectin with the PD‑1 axis drug balstilimab in metastatic triple‑negative breast cancer and reported the combination as “safe and well tolerated” in that abstract, without flagging clear interaction‑driven toxicity [7]. That single trial’s abstract does not constitute broader evidence of safety across oncology regimens nor does it catalog interaction case reports; it signals only that formal study is starting [7] [1].
3. Regulatory and clinical warnings — where concern comes from
Regulatory bodies and cancer centers have flagged potential risks. The U.S. FDA notes ivermectin can interact with other medications, including blood thinners, and warns about serious toxicity from overdoses; public‑facing oncology communications caution patients that unsupervised ivermectin use could worsen toxicity or blunt efficacy of proven cancer drugs [3] [8]. These warnings are precautionary and based on known pharmacology and adverse‑event reports rather than published oncology‑specific case reports of interactions [3] [8].
4. Mechanistic pathways that raise theoretical interaction risk
Mechanistic studies show ivermectin binds or influences proteins (EGFR, PAK1) and modulates efflux transporters and inflammatory signaling; these effects can resensitize tumor cells to chemotherapies in vitro and in animals and could theoretically change intracellular drug levels or toxicities when combined with agents like paclitaxel, cisplatin or other substrates of ABC transporters [6] [5] [9]. But extrapolating from cell lines to patient‑level pharmacokinetic interactions is not supported by current clinical reporting [6] [5].
5. Conflicting views and where clinicians stand
Some academic reviews and patient‑facing outlets urge caution and highlight the absence of human efficacy and safety data — advising oncologists to discourage unsupervised use because interactions or toxicity remain possible [1] [10] [11]. Conversely, small preclinical studies and early trialists pursuing repurposing emphasize potential synergy with chemotherapy and immunotherapy and argue that controlled clinical trials are needed to establish real‑world interaction profiles [9] [7] [4]. Both viewpoints appear in the literature: preclinical promise versus clinical uncertainty [9] [4].
6. What is missing — the evidence gaps that matter
Available sources do not mention any systematic case series or peer‑reviewed clinical case reports describing ivermectin causing a deleterious interaction with common oncology drugs (for example, tyrosine kinase inhibitors, taxanes, platinum agents, or checkpoint inhibitors) in humans; current human data are limited to small early‑phase study abstracts and expert cautionary statements [7] [1] [4]. There is a clear gap: no large safety databases or pharmacovigilance papers in the provided sources document oncology drug interactions attributable to ivermectin [1] [3].
7. Practical guidance for clinicians and patients
Oncology teams should treat ivermectin as experimental in cancer care: ask patients about over‑the‑counter or off‑label use, consider potential P‑glycoprotein and CYP‑mediated interactions, monitor INR and other labs if patients use anticoagulants, and prefer enrollment in formal trials rather than unsupervised self‑treatment [5] [3] [8]. Given the preclinical evidence of transporter and signaling effects, proactive review of drug lists and close monitoring are warranted even though specific, published oncology case reports of interaction are lacking [5] [1].
Limitations: this analysis is confined to the provided search results; broader databases or post‑2025 pharmacovigilance reports are not considered here. Available sources do not mention any peer‑reviewed clinical case reports of ivermectin interacting with standard oncology drugs beyond the early phase study abstracts and general regulatory cautions cited above [7] [1] [3].